Hepatocellular Carcinoma Pipeline Review, H2 2017 [Report Updated: 30112017] Prices from USD $2500
Hepatocellular Carcinoma Pipeline Review, H2 2017
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma Pipeline Review, H2 2017, provides an overview of the Hepatocellular Carcinoma Oncology pipeline landscape.
Hepatocellular carcinoma HCC is a type of cancer originates from a liver cell hepatocyte which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upperright part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes jaundice. The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is longterm chronic and iron overload in the body hemochromatosis. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma Oncology, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatocellular Carcinoma Oncology pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in PreRegistration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 12, 79, 51, 3, 72, 10 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 11, 7, 1, 26 and 2 molecules, respectively.
Hepatocellular Carcinoma Oncology pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma Oncology.
The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma Oncology by companies and universities/research institutes based on information derived from company and industryspecific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RD brief, MoA other developmental activities.
The pipeline guide reviews key companies involved in Hepatocellular Carcinoma Oncology therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Hepatocellular Carcinoma Oncology therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma Oncology
Reasons to buy
Procure strategically important competitor information, analysis, and insights to formulate effective RD strategies.
Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma Oncology.
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma Oncology pipeline depth and focus of Indication therapeutics.
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.
Original Article: Hepatocellular Carcinoma Pipeline Review, H2 2017 [Report Updated: 30112017] Prices from USD $2500
